Results for farmakokineetikas translation from Estonian to English

uitsetamine seoses tekkivate muutustega farmakokineetikas;
smoking in relation to induced alteration in pharmacokinetics

farmakokineetikas in vivo soolisi erinevusi ei ilmnenud.
no gender differences in pharmacokinetics were observed in-vivo.

bivalirudiini farmakokineetikas ei ole leitud soolisi erinevusi.
there are no gender effects in the pharmacokinetics of bivalirudin.

sugupoolega seotud erinevusi palifermiini farmakokineetikas ei täheldatud.
no gender-related differences were observed in the pharmacokinetics of palifermin.

linagliptiini farmakokineetikas neid muutusi ei peetud kliiniliselt olulisteks.
these changes in linagliptin pharmacokinetics were not considered to be clinically relevant.

raltegraviiri farmakokineetikas täheldati märkimisväärset inimestevahelist ja individuaalset varieeruvust.
considerable inter- and intra-individual variability was observed in the pharmacokinetics of raltegravir.

eri indiviidide vahelised erinevused vorikonasooli farmakokineetikas on äärmiselt suured.
the inter-individual variability of voriconazole pharmacokinetics is high.

olulist erinevust reslizumabi farmakokineetikas nende rühmade lõikes ei täheldatud.
no significant difference in the pharmacokinetics of reslizumab was observed across these groups.

10 sugu kliiniliselt olulisi sugudevahelisi erinevusi daptomütsiini farmakokineetikas ei ole leitud.
gender no clinically significant gender-related differences in daptomycin pharmacokinetics have been observed.

märkimisväärseid erinevusi reslizumabi farmakokineetikas nende neerufunktsiooni rühmade lõikes ei täheldatud.
no noteworthy differences in the pharmacokinetics of reslizumab were observed across these renal function groups.

meeste ja naiste võrdlemisel ei täheldatud nategliniidi farmakokineetikas kliiniliselt olulisi erinevusi.
no clinically significant differences in nateglinide pharmacokinetics were observed between men and women.

afroameerika ja valge rassi vahel ei leitud tselekoksiibi farmakokineetikas kliiniliselt olulisi erinevusi.
no clinically significant differences were found in pharmacokinetic parameters of celecoxib between african-americans and caucasians.

populatsiooni farmakokineetilises analüüsis ei leitud olulisi erinevusi erinevate rasside vahel lasofoksifeeni farmakokineetikas.
in a population pharmacokinetic analysis, no discernible difference in lasofoxifene pharmacokinetics was detected in different racial groups.

ruksolitiniibi manustamisel koos suure rasvasisaldusega toiduga ei täheldatud kliiniliselt olulisi muutusi ruksolitiniibi farmakokineetikas.
there was no clinically relevant change in the pharmacokinetics of ruxolitinib upon administration with a high-fat meal.

kui tenofoviirdisoproksiilfumaraati manustati koos lopinaviiri/ ritonaviiriga, ei täheldatud muudatusi lopinaviiri ja ritonaviiri farmakokineetikas.
when tenofovir disoproxil fumarate was administered with lopinavir/ ritonavir, no changes were observed in the pharmacokinetics of lopinavir and ritonavir.

lopinaviiri/ritonaviiri tablettidel on näidatud ka väiksemaid erinevusi farmakokineetikas sõltuvalt toidust kui lopinaviiri/ritonaviiri pehmekapslitel.
lopinavir/ritonavir tablets have also shown less pharmacokinetic variability under all meal conditions compared to lopinavir/ritonavir soft capsules.